New drug duo targets tough brain tumors in advanced cancer
NCT ID NCT05673928
Summary
This study is testing whether a combination of two drugs, tucatinib and T-DM1, can help control solid tumors that have spread to the brain. It is for up to 30 adults with HER2-positive metastatic cancer who have brain metastases that do not require immediate surgery or radiation. The main goal is to see if the drug combination can shrink or stop the growth of tumors in the brain and body, and to monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.